氯吡格雷抵抗基因多态性的研究进展  

The Research Progress of Genetic Polymorphism in Clopidogrel Resistance

作　　者：陈菲[1,2] 姚依群[1] 

机构地区：[1]北京军区总医院干一科,北京100700 [2]山西医科大学第二临床医学院,太原030001

出　　处：《医学综述》2014年第9期1635-1638,共4页Medical Recapitulate

摘　　要：氯吡格雷是临床上广泛使用的抗血小板药物,其对血小板的抑制具有个体差异性,部分患者在服用常规剂量氯吡格雷后存在抵抗现象而仍有缺血事件的发生,因此明确抵抗的机制将使患者受益。氯吡格雷抵抗可能受多方面因素的影响,目前认为基因多态性是一个重要原因。该文主要从氯吡格雷的吸收、活化和作用受体三方面的基因多态性进行综述。Clopidogrel is an antiplatelet drug widely used in clinical practice. However, clopidogrel- induced platelet-inhibition is patient-specific. Ischemic events still occur when clopidogrel resistance exists in some patients taking standard dose clopidogrel therapy. Therefore, to clarify the mechanism of resistance will be beneficial to patients. The mechanisms of clopidogrel resistance are affected by multiple factors. It is considered that genetic polymorphism is one of the most important reasons. Here is to make a review of the genetic polymorohism from the apects of clopidogrel absorption, activation and functionin, receptors.

关 键 词：氯吡格雷 氯吡格雷抵抗 基因多态性 

分 类 号：R541.4[医药卫生—心血管疾病]